<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Europe Reviews Tysabri Over Brain Infections</title>
	<atom:link href="http://www.pharmalot.com/2009/10/europe-reviews-tysabri-over-brain-infections/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2009/10/europe-reviews-tysabri-over-brain-infections/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 22:21:15 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Lisa Van Syckel</title>
		<link>http://www.pharmalot.com/2009/10/europe-reviews-tysabri-over-brain-infections/#comment-441994</link>
		<dc:creator>Lisa Van Syckel</dc:creator>
		<pubDate>Mon, 26 Oct 2009 17:08:27 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=19317#comment-441994</guid>
		<description>Mole Gerbil, your concerns would be considered more legit if you provided us with your real name..</description>
		<content:encoded><![CDATA[<p>Mole Gerbil, your concerns would be considered more legit if you provided us with your real name..</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Ed Silverman</title>
		<link>http://www.pharmalot.com/2009/10/europe-reviews-tysabri-over-brain-infections/#comment-441964</link>
		<dc:creator>Ed Silverman</dc:creator>
		<pubDate>Mon, 26 Oct 2009 16:35:25 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=19317#comment-441964</guid>
		<description>Hi Mole,

First, if you notice, I didn't post anything since last Friday morning. So I chose to get to it today, since Tysabri is always making news and my experience from the past is that not everyone notices breaking news or other items that occur on a Friday.

To answer your question, this is what I wrote in a previous comment to you: "I’m perfectly happy, however, to mention and link to stories from The Pink Sheet when they’re newsworthy - which could mean exclusive, insightful or simply different things that I’ve not seen elsewhere."

In this case, the Pink Sheet story about Tysabri was more detailed than what I saw on Bloomberg or in The Boston Globe, which were essentially long briefs.

Of course, there's a rub here. I had to walk a fine line - I included the basic info from The Pink Sheet, but I'm prevented from posting the entire story as part of my arrangement with my employer. So how would you know it's more detailed than other media? You won't unless you subscribe. Sorry, I can't help that. But I didn't omit necessary info.

At times, this may be an imperfect situation. But I've tried to be upfront about this. Like it or not, this is where things stand - my arrangement allows me to run Pharmalot on a part-time basis so as long as it doesn't cause some conflict with my job. And if there's an opportunity to post an item that offers sufficient info from the Pink Sheet, I'm happy to do so.

Meanwhile, I appreciate that you enjoy monitoring my activities. And please let me know if you believe an item appears to be illegitimate. By the way, I've disclosed my employment in all of the posts that linked to the Pink Sheet, as well as on the 'About Pharmalot' page - that detail was actually updated on the page several weeks ago. 

Regards
ed</description>
		<content:encoded><![CDATA[<p>Hi Mole,</p>
<p>First, if you notice, I didn&#8217;t post anything since last Friday morning. So I chose to get to it today, since Tysabri is always making news and my experience from the past is that not everyone notices breaking news or other items that occur on a Friday.</p>
<p>To answer your question, this is what I wrote in a previous comment to you: &#8220;I’m perfectly happy, however, to mention and link to stories from The Pink Sheet when they’re newsworthy - which could mean exclusive, insightful or simply different things that I’ve not seen elsewhere.&#8221;</p>
<p>In this case, the Pink Sheet story about Tysabri was more detailed than what I saw on Bloomberg or in The Boston Globe, which were essentially long briefs.</p>
<p>Of course, there&#8217;s a rub here. I had to walk a fine line - I included the basic info from The Pink Sheet, but I&#8217;m prevented from posting the entire story as part of my arrangement with my employer. So how would you know it&#8217;s more detailed than other media? You won&#8217;t unless you subscribe. Sorry, I can&#8217;t help that. But I didn&#8217;t omit necessary info.</p>
<p>At times, this may be an imperfect situation. But I&#8217;ve tried to be upfront about this. Like it or not, this is where things stand - my arrangement allows me to run Pharmalot on a part-time basis so as long as it doesn&#8217;t cause some conflict with my job. And if there&#8217;s an opportunity to post an item that offers sufficient info from the Pink Sheet, I&#8217;m happy to do so.</p>
<p>Meanwhile, I appreciate that you enjoy monitoring my activities. And please let me know if you believe an item appears to be illegitimate. By the way, I&#8217;ve disclosed my employment in all of the posts that linked to the Pink Sheet, as well as on the &#8216;About Pharmalot&#8217; page - that detail was actually updated on the page several weeks ago. </p>
<p>Regards<br />
ed</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: mole gerbil</title>
		<link>http://www.pharmalot.com/2009/10/europe-reviews-tysabri-over-brain-infections/#comment-441947</link>
		<dc:creator>mole gerbil</dc:creator>
		<pubDate>Mon, 26 Oct 2009 15:56:50 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=19317#comment-441947</guid>
		<description>ED: Forgot to mention that I'm glad to see you added a proper disclosure at the bottom of your piece.</description>
		<content:encoded><![CDATA[<p>ED: Forgot to mention that I&#8217;m glad to see you added a proper disclosure at the bottom of your piece.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: mole gerbil</title>
		<link>http://www.pharmalot.com/2009/10/europe-reviews-tysabri-over-brain-infections/#comment-441944</link>
		<dc:creator>mole gerbil</dc:creator>
		<pubDate>Mon, 26 Oct 2009 15:53:06 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=19317#comment-441944</guid>
		<description>Ed:
I believe your earlier reply to me said you link to these so-called breaking stories by the Pink Sheet when they offer your readers something out of the ordinary. This story was reported last friday by most major news media outlets. So, what's so different about the Pink Sheet or is this again part of your agreemenrt with Elsevier to promote its products?</description>
		<content:encoded><![CDATA[<p>Ed:<br />
I believe your earlier reply to me said you link to these so-called breaking stories by the Pink Sheet when they offer your readers something out of the ordinary. This story was reported last friday by most major news media outlets. So, what&#8217;s so different about the Pink Sheet or is this again part of your agreemenrt with Elsevier to promote its products?</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.151 seconds -->

